• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet shares down after Q1 miss

May 7, 2021 By Brian Buntz

InsuletInsulet (NSDQ:PODD) stock is down today — a day after the wearable insulin delivery system developer posted break-even Q1 results that were lower than analysts’ expectations.

The company, however, yesterday evening raised the low end of its revenue guidance range to 16–20%. The range was previously 15–20%.

The Acton, Mass.-based company a net loss of $0.0 million, or 0¢ per diluted share, on sales of $246.1 million for the three months ended March 31 — versus a net loss of –$2.1 million, or –3¢ per share for Q1 2020. Sales were up 27.4%.

Adjusted to exclude one-time items, earnings per share were $0.00. Analysts were looking for EPS of 8¢ on sales of $247.1 million.

“We’re off to a great start in 2021 with strong first-quarter revenue results,” said president and CEO Shacey Petrovic. “We are excited for the commercial launch of Omnipod 5, and the pivotal data we shared at ENDO 2021 clearly demonstrates the benefits and value it delivers to both children and adults.”

The company recently released data demonstrating that its Omnipod 5 automated insulin delivery system helped people with diabetes manage blood glucose while lowering HbA1c levels.

Insulet reaffirmed its expectations of achieving operating margin in the low double digits range at the end of the year.

Investors reacted by sending XPLT shares down –5.34% to $239.64 apiece by midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.

This story originally ran Thursday, May 6, 2021. Updated May 7 to include day-after stock price. 

 

Filed Under: Diabetes, Drug-Device Combinations, Featured Tagged With: automated insulin delivery system, Insulet, Omnipod 5

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS